These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Electrophysiological effects of MS-551, a new class III agent: comparison with dl-sotalol in dogs. Sen L; Cui G; Sakaguchi Y; Singh BN J Pharmacol Exp Ther; 1998 May; 285(2):687-94. PubMed ID: 9580614 [TBL] [Abstract][Full Text] [Related]
27. Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Singh BN; Deedwania P; Nademanee K; Ward A; Sorkin EM Drugs; 1987 Sep; 34(3):311-49. PubMed ID: 3315621 [TBL] [Abstract][Full Text] [Related]
28. Sotalol: a new beta-adrenergic blocker for ventricular arrhythmias. Cavusoglu E; Frishman WH Prog Cardiovasc Dis; 1995; 37(6):423-40. PubMed ID: 7777671 [TBL] [Abstract][Full Text] [Related]
29. Class III antiarrhythmic agents: the next wave. Bauman JL Pharmacotherapy; 1997; 17(2 Pt 2):76S-83S; discussion 89S-91S. PubMed ID: 9085343 [TBL] [Abstract][Full Text] [Related]
30. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome. Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304 [TBL] [Abstract][Full Text] [Related]
31. [Arrhythmias in pregnancy. How and when to treat?]. Flores JR; Márquez MF Arch Cardiol Mex; 2007; 77 Suppl 2():S2-24-S2-31. PubMed ID: 17972373 [TBL] [Abstract][Full Text] [Related]
32. [Chronic administration of beta blocking agents: left ventricular hemodynamics in myocardial infarctions during exercise (author's transl)]. Blümchen G; Esche HH Z Kardiol; 1981 Sep; 70(9):678-86. PubMed ID: 7303806 [No Abstract] [Full Text] [Related]
33. Differential effect of selected antiarrhythmic drugs on coronary artery ligation-induced ventricular arrhythmias on the right or left sides. Gautam CS; Sharma PL; Pandhi P Methods Find Exp Clin Pharmacol; 1995 Jun; 17(5):327-31. PubMed ID: 8830201 [TBL] [Abstract][Full Text] [Related]
34. Restacorin, a new antiarrhythmic drug: a review of its electrophysiologic and hemodynamic properties. Tuininga YS; Crinjns HJ; Kozma C; Rabloczky G; Jonkman JH; Lie KI Int J Clin Pharmacol Ther; 1994 Jun; 32(6):278-81. PubMed ID: 7921525 [TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia. Shi J; Ludden TM; Melikian AP; Gastonguay MR; Hinderling PH J Pharmacokinet Pharmacodyn; 2001 Dec; 28(6):555-75. PubMed ID: 11999292 [TBL] [Abstract][Full Text] [Related]
36. Sotalol hydrochloride (Betapace): a new antiarrhythmic drug. Porterfield JG; Porterfield LM Am J Crit Care; 1994 Jan; 3(1):80. PubMed ID: 8118498 [No Abstract] [Full Text] [Related]
37. Adenosine-Adenocard: a new intravenous antiarrhythmic agent for supraventricular tachycardia. Roach AC Crit Care Nurse; 1991; 11(7):78-9. PubMed ID: 2070638 [No Abstract] [Full Text] [Related]
38. Cardiovascular and respiratory effects of the beta-adrenoceptive antagonist sotalol: studies in health, angina pectoris and obstructive lung disease. Areskog NH; Cullhed I; Ringqvist I; Ström G Eur J Clin Pharmacol; 1975 Aug; 8(6):403-8. PubMed ID: 1233240 [TBL] [Abstract][Full Text] [Related]
39. Plasma clearance of propranolol and sotalol and hepatic drug-metabolizing enzyme activity. Sotaniemi EA; Anttila M; Pelkonen RO; Järvensivu P; Sundquist H Clin Pharmacol Ther; 1979 Aug; 26(2):153-61. PubMed ID: 455885 [TBL] [Abstract][Full Text] [Related]
40. [Proceedings: Hemodynamic and pharmacological findings during sotalol therapy in arterial hypertension]. Klein G; Schnelle K; Schinz A Z Kardiol; 1975; Suppl 2():86. PubMed ID: 1199380 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]